Skip to main content
. 2016 Jul 27;7(35):56842–56854. doi: 10.18632/oncotarget.10863

Figure 3. Effect of CYD 6-17 on β-catenin-mediated Wnt pathway.

Figure 3

A. Effect of CYD 6-17 on the expression of β-catenin mRNA (Upper panel) and protein (Lower panel) in T24-P, T24-B and UMUC3 cellsafter treatment. B. Effect of CYD 6-17 on β-catenin gene transcriptionactivityinT24-P, T24-B and UMUC3 cells transfected with TOP luciferase reporter gene. After normalizing with Renilla luciferase activity, the relative reporter gene activity in each cell line was calculated based on DMSO (=1). Data represented as mean ± SD (n=3). C. Western blot analyses of Bcl-2 and β-catenin downstream targets (CyclinD1 and Survivin) in TCC cell lines after treatment. D. Viability of CA-β-catenin or vector transfected T24 and UMUC3 cells after CYD 6-17 treatment was determined using MTT assay. Error bars represent SD; (n = 3). E. Expression of β-catenin and apoptosis markers (cleaved Caspase-3 and PAPR) from T24 and UMUC3 cells transfected with CA-β-catenin or vector then treated with CYD 6-17 (0 and 0.5 μM) for 24 h. F. Effect of β-catenin shRNAon TCC cells expressing CA-β-catenin treated with CYD 6-17. Left panel: Effect of shRNAs on the protein expression of β-catenin. Right panel: Effect of β-catenin shRNA on the viability of UMUC3 expressing CA-β-catenin treated with CYD 6-17.